FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4327761292> ?p ?o ?g. }

• W4327761292 abstract "Abstract Magnetic resonance imaging and computed tomography (CT) suffer from low contrast sensitivity and potential toxicity of contrast agents. To overcome these limitations, we developed and tested a new class of dual contrast agents based on polydopamine nanoparticles (PDA-NPs) that are functionalized and targeted with hyaluronic acid (HA). These nanoparticles (NPs) are chelated with Gd 3+ to provide suitable contrast. The targeted NPs were characterized through ultraviolet–visible spectroscopy (UV–vis), scanning electron microscopy (SEM), infrared Fourier transform (FTIR), and dynamic light scattering (DLS). The cytotoxicity was investigated on HEK293 cells using an MTT assay. The contrast property of synthesized Gd 3+ /PDA/HA was compared with Barium sulfate and Dotarem, as commercial contrast agents (CAs) for CT and MRI, respectively. The results illustrated that synthesized PDA-NPs have a spherical morphology and an average diameter of 72 nm. A distinct absorption peak around 280 nm in the UV–vis spectrum reported the self-polymerization of PDA-NPs. The HA coating on PDA-NPs was revealed through a shift in the FTIR peak of C=O from 1618 cm −1 to 1635 cm −1 . The Gd 3+ adsorption on PDA/HA-NPs was confirmed using an adsorption isotherm assay. The developed CA showed low in vitro toxicity (up to 158.98 µM), and created a similar contrast in MRI and CT when compared to the commercial agents. The r 1 value for PDA/HA/Gd 3+ (6.5 (mg/ml) −1 s −1 ) was more than Dotarem (5.6 (mg/ml) −1 s −1 ) and the results of the hemolysis test showed that at concentrations of 2, 4, 6, and 10 mg/ml, the hemolysis rate of red blood cells is very low. Additionally, the results demonstrated that PDA/HA/Gd 3+ could better target the CD 44 + -expressing cancer cells than PDA/Gd 3+ . Thus, it can be concluded that lower doses of developed CA are needed to achieve similar contrast of Dotarem, and the developed CA has no safety concerns in terms of hemolysis. The stability of PDA/HA/Gd 3+ has also been evaluated by ICP-OES, zeta potential, and DLS during 3 days, and the results suggested that Gd-HA NPs were stable." @default.
• W4327761292 created "2023-03-18" @default.
• W4327761292 creator A5010549796 @default.
• W4327761292 creator A5023659465 @default.
• W4327761292 creator A5041460867 @default.
• W4327761292 creator A5069783519 @default.
• W4327761292 creator A5082566209 @default.
• W4327761292 date "2023-03-18" @default.
• W4327761292 modified "2023-09-26" @default.
• W4327761292 title "Synthesis and characterization of Gd3+-loaded hyaluronic acid-polydopamine nanoparticles as a dual contrast agent for CT and MRI scans" @default.
• W4327761292 cites W1969043349 @default.
• W4327761292 cites W1989955363 @default.
• W4327761292 cites W1993470842 @default.
• W4327761292 cites W1996492048 @default.
• W4327761292 cites W2029881169 @default.
• W4327761292 cites W2047193607 @default.
• W4327761292 cites W2050566396 @default.
• W4327761292 cites W2060173048 @default.
• W4327761292 cites W2072651741 @default.
• W4327761292 cites W2083336655 @default.
• W4327761292 cites W2093385788 @default.
• W4327761292 cites W2099935411 @default.
• W4327761292 cites W2102914864 @default.
• W4327761292 cites W2121221447 @default.
• W4327761292 cites W2137244304 @default.
• W4327761292 cites W2140036864 @default.
• W4327761292 cites W2273106458 @default.
• W4327761292 cites W2296794835 @default.
• W4327761292 cites W2312265339 @default.
• W4327761292 cites W2325429999 @default.
• W4327761292 cites W2326973281 @default.
• W4327761292 cites W2407485215 @default.
• W4327761292 cites W2476529906 @default.
• W4327761292 cites W2618333020 @default.
• W4327761292 cites W2752698709 @default.
• W4327761292 cites W2758414633 @default.
• W4327761292 cites W2775929902 @default.
• W4327761292 cites W2791440299 @default.
• W4327761292 cites W2806713886 @default.
• W4327761292 cites W2889842659 @default.
• W4327761292 cites W2896094362 @default.
• W4327761292 cites W2896682297 @default.
• W4327761292 cites W2902459470 @default.
• W4327761292 cites W2908874869 @default.
• W4327761292 cites W2918110300 @default.
• W4327761292 cites W2918688542 @default.
• W4327761292 cites W2975797501 @default.
• W4327761292 cites W2980818847 @default.
• W4327761292 cites W3010921850 @default.
• W4327761292 cites W3016152430 @default.
• W4327761292 cites W3036296611 @default.
• W4327761292 cites W3040859487 @default.
• W4327761292 cites W3156651800 @default.
• W4327761292 cites W3201394451 @default.
• W4327761292 cites W3214980366 @default.
• W4327761292 cites W4210666585 @default.
• W4327761292 cites W5531942 @default.
• W4327761292 doi "https://doi.org/10.1038/s41598-023-31252-0" @default.
• W4327761292 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36934115" @default.
• W4327761292 hasPublicationYear "2023" @default.
• W4327761292 type Work @default.
• W4327761292 citedByCount "1" @default.
• W4327761292 countsByYear W43277612922023 @default.
• W4327761292 crossrefType "journal-article" @default.
• W4327761292 hasAuthorship W4327761292A5010549796 @default.
• W4327761292 hasAuthorship W4327761292A5023659465 @default.
• W4327761292 hasAuthorship W4327761292A5041460867 @default.
• W4327761292 hasAuthorship W4327761292A5069783519 @default.
• W4327761292 hasAuthorship W4327761292A5082566209 @default.
• W4327761292 hasBestOaLocation W43277612921 @default.
• W4327761292 hasConcept C105702510 @default.
• W4327761292 hasConcept C127413603 @default.
• W4327761292 hasConcept C13965031 @default.
• W4327761292 hasConcept C14631669 @default.
• W4327761292 hasConcept C155672457 @default.
• W4327761292 hasConcept C160892712 @default.
• W4327761292 hasConcept C171250308 @default.
• W4327761292 hasConcept C185592680 @default.
• W4327761292 hasConcept C192562407 @default.
• W4327761292 hasConcept C2777529286 @default.
• W4327761292 hasConcept C2778978742 @default.
• W4327761292 hasConcept C42360764 @default.
• W4327761292 hasConcept C71924100 @default.
• W4327761292 hasConceptScore W4327761292C105702510 @default.
• W4327761292 hasConceptScore W4327761292C127413603 @default.
• W4327761292 hasConceptScore W4327761292C13965031 @default.
• W4327761292 hasConceptScore W4327761292C14631669 @default.
• W4327761292 hasConceptScore W4327761292C155672457 @default.
• W4327761292 hasConceptScore W4327761292C160892712 @default.
• W4327761292 hasConceptScore W4327761292C171250308 @default.
• W4327761292 hasConceptScore W4327761292C185592680 @default.
• W4327761292 hasConceptScore W4327761292C192562407 @default.
• W4327761292 hasConceptScore W4327761292C2777529286 @default.
• W4327761292 hasConceptScore W4327761292C2778978742 @default.
• W4327761292 hasConceptScore W4327761292C42360764 @default.
• W4327761292 hasConceptScore W4327761292C71924100 @default.
• W4327761292 hasIssue "1" @default.
• W4327761292 hasLocation W43277612921 @default.
• W4327761292 hasLocation W43277612922 @default.
• W4327761292 hasLocation W43277612923 @default.

• next